CRPC w/ Bone Metastases - Results from #120

Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis. December 20, 2015

A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up December 17, 2015

Continuous use of enzalutamide in a patient who developed enzalutamide-induced thrombocytopenia December 17, 2015

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial December 17, 2015

Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature. November 24, 2015

[Vertebral metastases of urogenital carcinomas : Diagnosis and conservative therapy] October 20, 2015

Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trials October 19, 2015

Effects of concomitant use of abiraterone and/or enzalutamide with radium-223 on safety and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (EAP) October 14, 2015

Management of bone metastases in prostate cancer: a review September 22, 2015

Stochastic simulation of radium-223 dichloride therapy at the sub-cellular level September 9, 2015

Multimodal Partial Volume Correction - Application to 18F-Fluoride PET/CT bone metastases studies September 4, 2015

Bayer Supports Prostate Cancer Awareness Efforts in Communities Nationwide throughout September September 3, 2015

Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer August 28, 2015

Radium-223 for the treatment of castration-resistant prostate cancer August 13, 2015

Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival August 13, 2015

Optimal sequence of bone target drugs in metastatic prostatic cancer August 12, 2015

Health Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational Study August 11, 2015

Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future Prospects August 4, 2015

Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors July 26, 2015

The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer July 24, 2015

Page 7 of 10